Fireside Chat, moderated by Hartaj Singh
of Oppenheimer & Co., will be held on Wednesday, January
24, 2024, at 12:00pm
ET
PLYMOUTH
MEETING, Pa., Jan. 22,
2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancer and infectious diseases, today announced that it
will participate in a virtual fireside chat on the potential
treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's
President and CEO, Dr. Jacqueline
Shea, and Chief Medical Officer, Dr. Michael
Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins
University and a Principal Investigator in INOVIO's Phase 1/2
trial with INO-3107.
The fireside chat, titled "RRP - Disease Treatment Dynamics
& Urgent Need for Therapeutic Modalities," will take place on
Wednesday, January 24, 2024, at
12:00pm ET. Hartaj Singh, MBA,
Managing Director of Biotechnology Equity Research at Oppenheimer
& Co. Inc., will moderate the discussion.
A replay of the event will be made available shortly after its
conclusion and will be archived for 90 days under the Events and
Presentations page on the investor relations section of the
INOVIO website following the event.
Panel Participants
Simon
Best, MD, is an Associate Professor of Otolaryngology – Head
& Neck Surgery at Johns Hopkins Hospital. He is a
fellowship-trained laryngeal surgeon whose clinical interests are
focused on voice and airway disorders, with a particular interest
in RRP. He had led an NIH-funded
laboratory focused on RRP, participated in
clinical trials, spearheaded novel treatment paradigms, and sees
patients from across the world for this disease. In addition,
he treats the full range of voice disorders, including in
professional voice users and singers, vocal cord paralysis,
laryngeal cancer, precancerous vocal cord dysplasia,
benign laryngeal lesions (polyps, cysts, nodules), and laryngeal
and tracheal stenosis.
Dr. Jacqueline Shea has served as
INOVIO's President and Chief Executive Officer (CEO) since
May 2022. Dr. Shea joined the company
in March 2019 as Chief Operating
Officer (COO), serving as a key member of the executive team. Dr.
Shea has more than 25 years' experience in the life sciences and
biotech industries. Prior to joining INOVIO, she was the CEO at
Aeras, a not-for-profit organization dedicated to developing new
vaccines against tuberculosis (TB). She also held executive roles
at Emergent BioSolutions and was the General Manager and Vice
President of The Oxford-Emergent Tuberculosis Consortium. Dr. Shea
has dedicated much of her career to developing innovative products
to prevent and treat infectious diseases. Dr. Shea received a BSc
Hons in Applied Biology from the University of Bath and a Ph.D.
from the National Institute for Medical Research in the UK.
Dr. Michael Sumner leads INOVIO's clinical-stage pipeline
of DNA medicines. Dr. Sumner received his medical degree from
the University of London, is a
member of the Royal College of Physicians, and holds a Master of
Business Administration. He brings 30 plus years of extensive
pharmaceutical, medical and clinical experience driving many
late-stage product approvals and supporting successful commercial
products globally across multiple therapeutic areas. He previously
served as CMO of Orexo AB since 2013 and prior to that held
numerous European- and US-based leadership roles at Novartis, CSL
Behring, Novo Nordisk and Shire Pharmaceuticals.
About INOVIO
INOVIO is a biotechnology company
focused on developing and commercializing DNA medicines to help
treat and protect people from HPV-related diseases,
cancer, and infectious diseases. INOVIO's technology
optimizes the design and delivery of innovative DNA medicines that
teach the body to manufacture its own disease-fighting tools. For
more information, visit www.inovio.com.
Contacts
Media: Jennie Willson,
(267) 429-8567, jennie.willson@inovio.com
Investors: Thomas Hong, (267)
440-4298, thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-participate-in-virtual-fireside-chat-on-the-potential-treatment-of-recurrent-respiratory-papillomatosis-with-key-opinion-leader-302040262.html
SOURCE INOVIO Pharmaceuticals, Inc.